Solid Biosciences Inc. develops precision genetic medicines for rare neuromuscular and cardiac diseases. The company’s recurring news centers on its gene therapy portfolio, including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and SGT-601 for TNNT2-mediated dilated cardiomyopathy.
Company updates also cover clinical data from Duchenne studies, regulatory designations for SGT-003, scientific presentations in gene and cell therapy, capital-raising activity, inducement equity grants, investor conference participation, shareholder voting matters, and governance disclosures.
Solid Biosciences (Nasdaq: SLDB) announced that Bo Cumbo, President and CEO, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 10:30 AM ET. A live webcast will be available on the company Investor Events page, with a replay archived for 30 days.
Solid Biosciences (NASDAQ: SLDB) provided a 2026 outlook highlighting clinical progress across neuromuscular and cardiac programs and expanded access to its next‑generation capsid AAV‑SLB101.
Key points: 33 participants dosed with SGT‑003 in the Phase 1/2 INSPIRE Duchenne trial (safety cutoff 1/9/2026) with outpatient dosing enabled since Sept 2025; first participant enrolled in ex‑U.S. Phase 3 IMPACT Duchenne with dosing expected Q1 2026; first participant dosed in Phase 1b FALCON for SGT‑212 (FA); ARTEMIS sites activated for SGT‑501 (CPVT); FDA granted Orphan, Rare Pediatric Disease and Fast Track for SGT‑212; executed 50+ agreements for AAV‑SLB101.
Solid Biosciences (Nasdaq: SLDB) announced that the FDA granted Orphan Drug designation to SGT-212 for the treatment of Friedreich’s ataxia (FA). The company also holds Fast Track and Rare Pediatric Disease designations for SGT-212. The first participant has been dosed in FALCON, a Phase 1b first‑in‑human trial evaluating a novel dual‑route gene therapy (MRI‑guided intradentate nuclei infusion followed by IV) intended to restore frataxin. Initial clinical data are expected in H2 2026, subject to participant enrollment.
Solid Biosciences (NASDAQ: SLDB) announced dosing of the first participant in FALCON, its Phase 1b first‑in‑human trial of SGT‑212 for Friedreich’s ataxia on January 12, 2026. SGT‑212 uses a dual‑route approach: MRI‑guided stereotactic intradentate nuclei (IDN) infusion to the cerebellar dentate nuclei followed by an intravenous infusion, aiming to restore frataxin. Intra‑procedural MRI confirmed IDN targeting and coverage above company thresholds. The company expects preliminary safety insights in coming months and an initial data update in H2 2026, subject to participant enrollment.
Solid Biosciences (Nasdaq: SLDB) announced that President and CEO Bo Cumbo will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 5:15 p.m. PT (8:15 p.m. ET). A live webcast will be available on the company's Investors Events page, and a replay will be archived for 30 days.
This presentation provides investors and analysts access to management commentary and updates via webcast.
Solid Biosciences (Nasdaq: SLDB) announced on January 5, 2026 an inducement grant of 7,000 restricted stock units (RSUs) to a newly hired employee under the company’s 2024 Inducement Stock Incentive Plan. The RSUs vest in four equal annual installments on each one-year anniversary of the grant date through the fourth anniversary, subject to the employee’s continued service.
The grant was made as an inducement material to the employee’s acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences (Nasdaq: SLDB) announced that Duchenne muscular dystrophy was added to the U.S. Recommended Uniform Screening Panel (RUSP) on Dec. 16, 2025, making it recommended for universal newborn screening.
Solid noted its long-term advocacy role, including participation on PPMD’s steering committee and a New York state pilot completed in 2021. The company said RUSP inclusion is expected to accelerate detection and enable earlier access to specialists, supportive interventions, and treatments.
Solid reiterated its focus on advancing its investigational gene therapy SGT-003 for Duchenne while celebrating earlier diagnosis and resource access for families.
Solid Biosciences (Nasdaq: SLDB) will present new data on its next-generation capsid AAV-SLB101 and cardiac gene therapy pipeline at the 22nd Global CardioVascular Clinical Trialists Forum, December 8-10, 2025, in Washington, D.C.
Chief Medical Officer Gabriel Brooks, M.D. will present two talks, a poster on AAV-SLB101 showing potent cardiac tropism and initial clinical safety, and join two panels; Nicolas Christoforou, Ph.D. will present preclinical work on a gene therapy for catecholaminergic polymorphic ventricular tachycardia (CPVT) and join a panel.
Presentations will be posted after the conference on the company’s Scientific Publications & Presentations page.
Solid Biosciences (Nasdaq: SLDB) announced on December 1, 2025 that it granted a total of 23,284 restricted stock units (RSUs) to two newly hired employees as inducement awards under the company’s 2024 Inducement Stock Incentive Plan.
The RSUs vest in four equal installments on each one-year anniversary of the grant date through the fourth anniversary, and vesting is subject to the employees' continued service. The awards were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences (Nasdaq: SLDB) announced on Dec 1, 2025 that the FDA granted Rare Pediatric Disease designation to SGT-212, its investigational dual-route gene therapy for Friedreich’s ataxia (FA).
SGT-212 delivers the full-length frataxin gene via both intradentate nucleus (IDN) and intravenous (IV) administration and has previously received Fast Track designation. The Rare Pediatric Disease designation makes SGT-212 potentially eligible for a pediatric priority review voucher (PRV), which can expedite future biologics review or be sold or transferred. The company said screening is underway for the FALCON Phase 1b first-in-human trial.